Silence Therapeutics (SLN)
NASDAQ: SLN
· Real-Time Price · USD
5.78
-0.16 (-2.69%)
At close: May 30, 2025, 3:59 PM
6.09
5.36%
After-hours: May 30, 2025, 04:34 PM EDT
-2.69% (1D)
| Bid | 5.21 |
| Market Cap | 272.99M |
| Revenue (ttm) | 26.21M |
| Net Income (ttm) | -56.93M |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -3.78 |
| Forward PE | -10.25 |
| Analyst | Buy |
| Ask | 6.1 |
| Volume | 181,707 |
| Avg. Volume (20D) | 229,145 |
| Open | 6.04 |
| Previous Close | 5.94 |
| Day's Range | 5.58 - 6.05 |
| 52-Week Range | 1.97 - 22.46 |
| Beta | 1.19 |
Analyst Forecast
According to 0 analyst ratings, the average rating for SLN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-15.45%
Silence Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
3 weeks ago · businesswire.com
Silence Therapeutics Welcomes Tim McInerney to Board of DirectorsLONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
